Alterity Therapeutics Ltd. (AU:ATH) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Alterity Therapeutics has made significant strides in 2024 with its lead drug, ATH434, nearing the completion of a pivotal Phase 2 trial for Multiple System Atrophy (MSA). Promising preliminary results and ongoing research bolster its potential in treating neurodegenerative diseases, especially Parkinsonian disorders. As the company anticipates major data releases in 2025, it continues to engage with the scientific community to advance its development programs.
For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.
